Case Reports of Cancer Patients with Hepatic Metastases Treated by Standardized Plant Immunomodulatory Preparations


  • Tibor Hajto Department of Immunology and Biotechnology, University Pecs, Faculty of Medicine, Pecs, Hungary
  • Angelika Kirsch Private Praxis, Paradiesstr. 14, Binningen CH-4102, Switzerland



Hepatic metastasis, immunomodulation, mistletoe extract, mistletoe lectin, arabinoxylan, MGN-3, wheat germ extract, benzoquinone.


 Background:Metastatic hepatocellular carcinoma often has a multifocal tumor pattern with markedly depressed hepatic function. Hepatic resection in many cases results in no long-term benefit. After a chemotherapy hepatic tumors rarely disappear completely and the duration of responses is short. In the last decades growing evidence suggested that a disturbed balance in the innate system can also play a role in the poor prognosis of hepatic tumors.

Objectives:The aim of this article is to present and discuss several favorable clinical responses of patients with hepatic metastases who parallel to conventional oncologic therapy, were treated with immunologically effective and standardized plant extracts.

Course of Therapy and Results: In accordance with the bell-shaped dose-response relationship of mistletoe lectins (MLs), the patients were treated with a fermented mistletoe extract (ME) preparation, standardized for the active sugar-binding lectin contents. Thus, an optimal dose between 0.5 and 1.0ng/kg MLs was given twice a week subcutaneously. In addition to ML therapy, a heteropolysaccharide rice bran preparation standardized for arabinoxylan (12-45mg/kg MGN-3/BiobranR twice a week) and wheat germ extract (WGE) standardized for 2, 6-dimethoxy-p-benzoquinone (50-80mg/kg AvemarR four times a week) was also given. In these case reports the clinical progress of seven patients showed a complete or nearly complete remission of hepatic metastases.

Conclusion:ML, MGN-3 and WGE seem to be potent candidates to be regarded as a supportive therapy to surgery, hormone treatment or chemotherapy for patients with hepatic metastases. These case reports require further clinical studies.


Cady B, Macdonald JS, Gunderson LL. Cancer of the hepatobiliary system. In: DeVita VT, Hellman S, Rosenberg SA, Eds. Cancer: principles and practice of oncology. Philadelphia, JB Lippincott Co 1985; p. 741.

Nagtegaal ID, Klein-Kranenbarg E, Mulder-Stapel A, Hermans J, Van den Velde CJH, Han J, et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect. A histopathological and immunohistochemical study. BMC Cancer 2001; 1: 7-16.

Baskic D, Acimovic L, Samardzic G, Vujanovic NL, Arsenijevic NN. Blood monocytes and tumor-associated macrophages in human cancer: differences in activation levels. Neoplasma 2001; 48: 169-74.

Ostrand-Rosenberg S, Sinka P. Myeloid derived suppressor cells linking in inflammation and cancer. J Immunol 2009; 182: 4499-506.

Mantovani A. Inflammation and cancer: the macrophage connection. Medicina (Buenos Aires) 2007; 67(Suppl II): 32-34.

Sanchez-Torres C, Garcia-Romo GS, Cornejo-Cortes MA, et al. CD16+ and CD16- human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells. Int Immunol 2001; 13: 1571-81.

Terabe M, Berzofsky JA. The role of NKT cells in tumor immunology. Adv Cancer Res 2008; 101: 277-348.

Lotfi R, Schrezenmeier H, Lotze MT. Immunotherapy for cancer: promoting innate immunity. Front Biosci 2009; 14: 818-32.

Elluru S, Duong van Huyen JP, Wootla B, Delignat S, Prost F, Negi VS, et al. Tumor regressive effects of Viscum album preparations. Exploration of immunomodulatory mechanisms. Medicina (Buenos Aires) 2007; 67(Suppl. II): 85-89.

Hajto T, Hostanska K, Gabius H-J. Modulatory potency of the β-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 1989; 49: 4803-808.

Hajto T, Hostanska K, Weber K, Zinke H, Fischer J, Mengs U, et al. Effect of a recombinant lectin, Viscum album agglutinin (rVAA) on secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo. Nat Immun 1998; 16: 34-46.

Hajto T, Hostanska K, Berki T, Boldizsár F, Németh P. Oncopharmacological perspectives of a plant lectin (Viscum album agglutinin-I): Overwiew of recent results from in vitro experiments and in vivo animal models, and their possible relevance for clinical applications. eCAM 2005; 2: 59-67.

Hajto T, Fodor K, Aponyi I, Pallai ZS, Balogh P, Németh P, et al. Unexpected different binding of mistletoe lectins from plant extracts to immobilized lactose and N-acetylgalactosamine. Anal Chem Insights 2007; 2: 43-50.

Müthing J, Burg M, Möckel B. Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally α2-6-sialylated neolacto-series gangliosides. Glycobiol 2002; 12: 485-97.

Müthing J, Meisen I, Bulau P, Langer, M, Witthohn K, Lentzen H, et al. Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Ac alpha 2-6Gal beta 1-4GlcNAc residues. Biochemistry 2004; 43: 2996-3007.

Hostanska K, Hajto T, Spagnoli GC, Saller R. A plant lectin, Viscum album agglutinin-I (VAA-I), stimulates cellular parameters of natural immunity in vivo and induces cytokine gene expression and apoptosis in cultures of peripheral blood mononuclear cells in vitro. Nat Immun 1996-97; 15: 196-201.

Ghoneum M. Enhancement of human natural killer cell activity by modified arabinoxylan from rice bran (BioBrab/MGN-3). Int J Immunotherapy 1998; 14: 89-99.

Ghoneum M, Matsuura M. Augmentation of macrophage phagocytosis by modified arabinoxylan from rice bran (BioBran/MGN-3). Int J Immunopath Pharmacol 2004; 17: 283-92.

Hidvégi M, Rásó E, Tömösközi-Farkas R, Szende B, Paku S, Prónai L, et al. MSC, a new benzoquinone-containing natural product with antimetastatic effect. Cancer Biother Radiopharmaceut 1999; 14: 277-89.

Szent-Györgyi A. Biological oxidation and cancer. Int J Quant Chem Quant Biol Symp 1982; 9: 27-38.

Jakab F, Mayer Á, Hoffmann A, Hidvégi M. First clinical data of a natural immunomodulator in colorectal cancer. Hepato-Gastroenterology 2000; 47: 393-95.

Boros LG, Nichellatti M, Shoenfeld Y. Fermented wheat germ extract (Avemar) in the treatment of cancer and autoimmune disease. Ann NY Sci 2005; 1051: 529-42.

Fajka-Boja R, Hidvégi M, Shoenfeld Y, Ion G, Demydenko D, Tömösközi-Farkas R, et al. Fermented wheat germ extract induces apoptosis and downregulation of major histocompatibility complex class I proteins in tumor T and B cell lines. Int J Onc 2002; 20: 563-70.

Ghoneum M, Gollapudi S. Modified arabinoxylan rice bran BioBran/MGN-3 enhances yeast-induced apoptosis in human breast cancer cells in vitro. Anticancer Res 2005; 25: 859-70.

Hajto T, Hostanska K, Steinberg F. Beta-galactoside-specific lectin from clinically applied mistletoe extract reduces tumor growth by augmentation of host defense system. Blut 1990; 61: 164.

Doung van Huyen JP, Delignat S, Bayry J. Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. Cancer Lett 2006; 243: 32-37.

Hajto T, Hostanska K, Fornalski M, Kirsch A. Anti-tumor activity of an immunomodulator: the beta-galactoside-specific mistletoe lectins given in mistletoe extracts (Iscador). Deutsch Zschr Onkol 1991; 23: 1-6.

Kirsch A. Successful treatment of metastatic malignant melanoma with Viscum album extract (Iscador M). J Alternat Complem Med 2007; 13: 443-445.

Kirsch A, Hajto T. Case reports of sarcoma patients with optimized lectin-oriented mistletoe extract therapy. J Alt Compl Med 2011; 17: 973-79.

Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B. Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemio-logical cohort study in Germany and Switzerland. Drug Res 2004; 54: 456-66.

Tsunekawa H. Effect of long-term administration of immunomodulatory food on cancer patients completing conventional treatments. Clin Phamacol Ther 2004; 14: 295-302.




How to Cite

Tibor Hajto, & Angelika Kirsch. (2013). Case Reports of Cancer Patients with Hepatic Metastases Treated by Standardized Plant Immunomodulatory Preparations . Journal of Cancer Research Updates, 2(1),  1–9.